Drug
[11C]raclopride
[11C]raclopride is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_1
1
33%
Ph phase_4
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Terminated1
Completed1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
terminated133%
completed133%
not_yet_recruiting133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_1
A Multimodal Imaging Study of Dopamine in Early Psychosis
NCT06977308
terminatednot_applicable
Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET
NCT02152670
completedphase_4
Monoamine Contributions to Neurocircuitry in Eating Disorders
NCT02020408
Clinical Trials (3)
Showing 3 of 3 trials
NCT06977308Phase 1
A Multimodal Imaging Study of Dopamine in Early Psychosis
NCT02152670Not Applicable
Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET
NCT02020408Phase 4
Monoamine Contributions to Neurocircuitry in Eating Disorders
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3